Wyeth/Interneuron Redux descheduling proposal by DEA issues one year after approval of obesity agent.
DEA TO CONTINUE TO MONITOR FENFLURAMINE ABUSE POTENTIAL FOLLOWING DESCHEDULING of the agent and its isomers, including dexfenfluramine (Wyeth-Ayerst/Interneuron's Redux), the Drug Enforcement Administration stated in a May 6 notice proposing to remove fenfluramine (Wyeth's Pondimin) from Schedule IV of the Controlled Substances Act. "In light of the increasing availability and use of fenfluramine, particularly in combination with phentermine, and possible public health and safety risks including neurotoxicity, primary pulmonary hypertension and reports that fenfluramine may have pharmacological similarity to some hallucinogenic substances, DEA will carefully monitor the abuse, trafficking and diversion indicators regarding this substance," the notice states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth